You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

29 Results
Regimen
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
May 2019
Regimen
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    methotrexate - oral tablets
Exceptional Access Program
    tretinoin (ATRA)
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Intent: Curative
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
ODB - General Benefit
    dexamethasone
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
New Drug Funding Program
    Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia
ODB - General Benefit
    dexamethasone
Nov 2024

Pages